MindMed shareholders approve 2025 Equity Incentive Plan authorizing 4.5M new shares

Definium Therapeutics, Inc.

Plan replaces prior stock option and restricted share unit plans; 4,500,000 common shares reserved.
All six director nominees (Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, Carol A. Vallone) elected with >99% votes for each.
KPMG LLP ratified as independent auditor for the next year (42,583,160 for, 267,331 withheld).
Plan approved by shareholders: 28,452,155 for, 581,911 against, 110,688 abstain, 13,705,737 broker non-votes.
Annual meeting held June 12, 2025; 56.7% of outstanding shares voted, quorum present.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.